NYSE:IBIO iBio (IBIO) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free IBIO Stock Alerts $1.98 +0.17 (+9.39%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share Today's Range$1.83▼$2.0450-Day Range N/A52-Week Range$1.02▼$19.33Volume327,800 shsAverage Volume2.56 million shsMarket Capitalization$17.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsSocial Media Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About iBio Stock (NYSE:IBIO)iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesMay 14, 2024 | finanznachrichten.deiBio, Inc.: iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | americanbankingnews.comiBio (NYSE:IBIO) Shares Down 1.9% May 13, 2024 | globenewswire.comiBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateApril 5, 2024 | investorplace.com3 Healthcare Stocks Short Sellers Are Prescribing for TroubleMarch 28, 2024 | markets.businessinsider.comKodiak Sciences Inc Registered Shs hosts conference call for investorsSee More Headlines Company Calendar Today5/20/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:IBIO Previous SymbolNYSE:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone302-355-0650Fax302-356-1173Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-34,258.00% Return on Equity-109.36% Return on Assets-42.02% Debt Debt-to-Equity Ratio0.04 Current Ratio1.69 Quick Ratio0.91 Sales & Book Value Annual Sales$2.38 million Price / Sales7.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book0.69Miscellaneous Outstanding Shares8,620,000Free Float8,527,000Market Cap$17.07 million OptionableN/A Beta-3.22 Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 53)Ph.D., CEO & Chief Scientific Officer Comp: $577.31kMr. Felipe Duran (Age 44)Chief Financial Officer Comp: $1.07MStephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.General CounselMr. Robert B. Kay (Age 84)Interim Secretary & Interim Treasurer Comp: $92.69kKey CompetitorsBiofronteraNASDAQ:BFRIPulmatrixNASDAQ:PULMASLAN PharmaceuticalsNASDAQ:ASLNAinosNASDAQ:AIMDVaccinexNASDAQ:VCNXView All CompetitorsInstitutional OwnershipIkarian Capital LLCBought 600,000 shares on 5/17/2024Ownership: 6.961%View All Institutional Transactions IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed in 2024? iBio's stock was trading at $1.26 at the start of the year. Since then, IBIO shares have increased by 57.1% and is now trading at $1.98. View the best growth stocks for 2024 here. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Sorrento Therapeutics (SRNE), Tesla (TSLA), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arista Networks (ANET), Aquestive Therapeutics (AQST), Alphatec (ATEC), Alibaba Group (BABA), Boxlight (BOXL) and Ford Motor (F). Who are iBio's major shareholders? iBio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (6.96%). How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:IBIO) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.